Ocugen Inc, a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe, ...

In this Healio Video Perspective from the ARVO meeting, SriniVas R. Sadda, MD, FARVO, discusses a long-term study evaluating MCO-010 for the treatment of retinitis pigmentosa.

A breakthrough treatment has allowed damaged retinal cells to regenerate themselves. The current research has been conducted on mice, but the pathways are the same in humans, which opens hope for a ...

Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Retinitis pigmentosa (RP) is a group of genetic eye conditions that leads to incurable blindness.In the progression of symptoms for RP, night blindness generally precedes tunnel vision by years or ...

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc., a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to ...

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of OCU400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea. Date. 2025-06-05 07:16:07. Share on Facebook; ...

Luke Johnston, a 10-year-old diagnosed with Retinitis Pigmentosa, is losing his eyesight, prompting his friends and family to raise millions to fund a clinical trial for a potential cure.

Brain-computer interface (BCI) developer Science Corporation today said it submitted its Prima retinal implant for CE mark ...